跳至主要内容
临床试验/NCT01089283
NCT01089283Unknown不适用

I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic

Tel-Aviv Sourasky Medical Center1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2010年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
80
试验地点
1

研究概览

简要总结

Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors. There are gene mutations that increase the risk for the disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if there is a difference between the metabolic brain function of Parkinson patients that carry one of the two mutations to Parkinson patients with no known mutation.

Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA genes, Parkinson patients with no known mutation and healthy volunteers as a control group.

The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv Sourasky Medical Center Nuclear Medicine Institute.

The examination results will be given to the participants by a doctor from the neurology department.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosed Parkinson patients with known genetic characteristics

排除标准

  • patients unable to understand and sign an informed consent
  • patients in medical condition that does not allow them to stay still during the examination

研究者

申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验

Ioflupane I123 (DaTSCAN) and Positron Emission... | 临床试验